Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 429
  • Home
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2022  |  Volume : 17  |  Issue : 5  |  Page : 482-492

Design and synthesis of some novel triazine-tyrosine hybrids as potential agents for the treatment of multiple sclerosis


1 Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran
2 Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences; Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Science, Isfahan, I.R. Iran
3 Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Science, Isfahan University of Medical Sciences; Department of Pharmacology and Toxicology, Isfahan, I.R. Iran

Correspondence Address:
Ghadam Ali Khodarahmi
Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran
I.R. Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1735-5362.355208

Rights and Permissions

Background and purpose: One of the most noteworthy methods to slow down multiple sclerosis (MS) progress is a decrease of lymphocyte cells via S1P1 receptor modulating. Here, a series of S1P1 receptor modulators were designed and investigated for their ability to decrease lymphocytes in a rat model. Experimental approach: Molecular docking was performed to compare the binding mode of desired compounds 5a-f with fingolimod to the active site of the S1P1 receptor, theoretically. To prepare desired compounds, 5a-f, cyanuric chloride was reacted with different amines, a-f, which then converted to 4a-f compounds through reaction with N-boc-Tyr-OMe ester. Finally, deprotection of the carboxyl and amino groups was carried out to obtain 5a-f as final products. Lymphocyte counting in the rat model was carried out using flow cytometry to evaluate the efficacy of the suggested compounds. Findings / Results: All compounds exhibited lower binding energy than fingolimod. Compound 5e with ΔG= -8.10 kcal/mol was the best compound. The structure of the compounds was confirmed spectroscopically. The in vivo study proved that compounds 5b and 5a decreased the lymphocytes level at 0.3 and 3 mg/kg, respectively. Conclusion and implications: The desired compounds were well fitted in the receptor active site following molecular docking studies. The results of lymphocyte count revealed that compounds 5a and 5b with propyl and ethyl substitutes showed the maximum activity in vivo. Finally, the results of the present project can be used for forthcoming investigations towards the design and synthesis of novel potential agents for MS treatment.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed322    
    Printed2    
    Emailed0    
    PDF Downloaded52    
    Comments [Add]    

Recommend this journal